Short name: MION, central moiety: Fe3+/Fe2+, relaxivity: r1=3.7, r2=6.5, B0=0.47T MIONs are under development (preclin.) as contrast agents (taken up by the RES) for MR angiography, MR lymphography, tumor detection and detection of infarctioned tissue. Also called monodisperse iron oxide nanoparticles or nanocompounds.
• Share the entry 'Monocrystalline Iron Oxide Nanoparticle':
(CLIO) This new class of contrast agents under development consists of MION reacted with crosslinking agents (e.g. epichlorohydrin used in the manufacture of dextran particles) that connect the partly free-floating dextran chain around the iron core.
Contrast agent with a preferential intracellular distribution.
Intracellular agents (such as manganese derivatives and ultrasmall superparamagnetic iron oxide), exhibit a flow- and metabolism-dependent uptake. These properties may allow delayed imaging, similar to isotopic methods.
Phospholipid liposomes are rapidly sequestered by the cells in the reticuloendothelial system (RES), primarily in the liver. For imaging of the liver, liposomes may be labeled with MR contrast medium, both positive (T1-shortening) paramagnetic media, and negative (T2-shortening) superparamagnetic media.
Several other nonliposome MR contrast media are also taken up by the RES, e.g.:
•
] and 3 definitions [
]
Further Reading:
Random Page
top
